People with Type 2 diabetes taking semaglutide appeared to have a significantly lower risk of developing Alzheimer's compared to patients taking seven other diabetes drugs, researchers reported.

The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may reduce the risk of Alzheimer's disease, a new study published Thursday finds.

Type-2 diabetes patients taking the active ingredient in the drugs, semaglutide, "had a significantly lower risk" of developing the disease, the study found

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy. These medications mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.